Asthma biologics to come under ICER microscope

25 April 2018

US prices for biologics to treat moderate to severe asthma are to be considered as part of a comparison announced by the USA's Institute for Clinical and Economic Review (ICER).

The report assessing the comparative clinical effectiveness and value of the treatments is set to be reviewed during a November 2018 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees.

There will be five drugs included in the report. These are Dupixent (dupilumab), from Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN), Xolair (omalizumab) from Roche (ROG: SIX) and Novartis (NOVN: VX), GlaxoSmithKline’s (LSE: GSK) Nucala (mepolizumab), Cinqair (reslizumab) from Teva Pharmaceutical Industries (NYSE: TEVA) and AstraZeneca’s (LSE: AZN) Fasenra (benralizumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK